ReviewJournal of the Korean Society of Radiology2025
Radioembolization: Technical Tips and Follow-Up Imaging.
Review in Journal of the Korean Society of Radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Preface to the Special Issue on Transarterial Radioembolization for Hepatocellular Carcinoma].Journal of the Korean Society of Radiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transarterial radioembolization (TARE) is a minimally invasive treatment modality for hepatocellular carcinoma (HCC) that delivers targeted radiation via radioactive microspheres. The procedure entails selective catheterization of the hepatic artery, followed by infusion of yttrium-90-labeled microspheres directly into the arterial supply of the tumor. Several technical strategies are employed to optimize precise radiation delivery while minimizing exposure to surrounding healthy liver tissue. Post-procedure imaging is crucial for assessing therapeutic efficacy. Contrast-enhanced CT or MRI is routinely performed to evaluate tumor response, which may manifest as reductions in tumor size, decreased vascularity, or increased necrosis. It is important to recognize that radioembolization-induced changes in the liver parenchyma can mimic tumor recurrence, which may lead to unnecessary additional interventions if misinterpreted. Follow-up imaging also plays an essential role in identifying potential complications, including non-target radiation injury and disease progression. Overall, TARE has demonstrated promising outcomes in improving survival and quality of life for patients with HCC, establishing itself as a valuable option within the multidisciplinary management of liver cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.